DSIP: A Sleep Peptide Named in 1977, With No Known Receptor

Delta sleep-inducing peptide is sold for sleep, and its name is the entire sales pitch. It was isolated in 1977 from rabbit cerebral venous blood and named after an early brain-wave effect in rabbits. A review of the field put the position plainly: the hypothesis regarding DSIP as a sleep factor is extremely poorly documented and still weak. The DSIP gene, its protein and any related receptor have not been isolated.^[1]

The name is a hypothesis, not a description

In 1977 a group in Basel isolated a substance from the blood of rabbits and, after it increased slow-wave (delta) brain activity when infused into rabbit brains, called it delta sleep-inducing peptide.^[2] Names given at the point of discovery stick regardless of what follows. Nearly fifty years later the compound is sold under a label that states an effect the literature never established.

The review’s own title, “a still unresolved riddle,” is an unusually candid summary from inside a field. It records that the link between DSIP and sleep has never been further characterized, and that the peptide’s natural occurrence and biological activity remain obscure.^[1]

Why the missing receptor settles it

Most arguments about supplement evidence are about trial quality: sample sizes, controls, endpoints. This one is simpler and comes earlier. A peptide produces effects by binding something. If no receptor has been identified, there is no demonstrated route by which the molecule could produce the effect its name claims.

The DSIP gene, its protein and any related receptor have not been isolated.

The review attributes the stalled state of the field partly to this: the absence of an isolated gene, protein and receptor is why the sleep link was never characterized further.^[1] The review is from 2006. We are describing what it documents, not asserting that nothing has happened in the two decades since. In what we found, no subsequent body of clinical evidence has displaced it.

If sleep is the actual problem

• DSIP is not an approved medicine anywhere and is sold as a research chemical, with no identity, purity or dose guarantee.
• Poor sleep has causes worth identifying. Sleep apnea in particular is common, treatable, and strongly associated with excess weight.
• Cognitive behavioral therapy for insomnia has a substantial randomized evidence base and is the first-line recommendation in guidelines.
• A peptide named after the effect you want is not evidence that it produces the effect you want.

For sleep-disordered breathing, where there is an approved drug and a randomized trial, see Zepbound for sleep apnea. For what happened to sleep quality in people starting a GLP‑1, see sleep and mood on a GLP-1. For the regulatory position on research-use peptides, see what FDA actually said about BPC-157. The three small insomnia trials, and FDA's note on emideltide, are summarized on our DSIP profile.